Recent 8-K filings for SGHT

• May 06, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M

  Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.

• Apr 23, 2026 23:59 UTC litigation materiality 0.70 positive item 7.01item 9.01

  Sight Sciences wins patent case vs Alcon; awarded $55.4M damages + ongoing royalty

  Final judgment in Sight Sciences' patent infringement case against Alcon for Hydrus Microstent.

• Mar 30, 2026 23:59 UTC litigation materiality 0.80 positive item 7.01item 9.01

  Sight Sciences secures court order preserving willful-infringement verdict against Alcon; $34M award plus royalties

  Order upholds jury finding that Alcon willfully infringed three Sight Sciences patents.

• Mar 04, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M

  Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.

• Feb 03, 2026 23:59 UTC other materiality 0.15 neutral item 1.01

  Sight Sciences amends headquarters lease, extends term to December 2028

  Second Amendment to lease extends term 26 months from Nov 1, 2026 to Dec 31, 2028.

• Jan 13, 2026 23:59 UTC earnings materiality 0.60 neutral item 2.02item 9.01

  Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY

  Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.

• Nov 06, 2025 23:59 UTC earnings materiality 0.75 neutral item 2.02item 5.02item 7.01item 9.01

  Sight Sciences Q3 revenue $19.9M, raises FY25 guidance; promotes COO and CFO

  Surgical Glaucoma revenue $19.7M (+6% YoY); Dry Eye revenue $0.2M (-88%) as company focuses on reimbursed access.

• Oct 17, 2025 23:59 UTC regulatory materiality 0.75 positive item 7.01item 8.01item 9.01

  Sight Sciences gets Medicare pricing for TearCare from Novitas and FCSO; $1,141.59 fee

  Two MACs set jurisdiction-wide pricing for CPT 0563T (TearCare) at $1,141.59, effective Jan 1, 2025.

• Sep 30, 2025 23:59 UTC debt materiality 0.60 neutral item 1.01item 9.01

  Sight Sciences extends interest-only period to Feb 2027, ups Tranche 3 to $25M

  Interest-only period extended six months to February 1, 2027.

• Aug 27, 2025 23:59 UTC other_material materiality 0.75 negative item 2.05item 5.02item 7.01

  Sight Sciences cuts 20% workforce; CCO departs; reaffirms FY revenue guidance

  Reduces headcount by 43 (~20% of global workforce); expects cash restructuring charge of $2.7M-$3.0M in Q3 2025.

• Aug 07, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  Sight Sciences Q2 2025 revenue $19.6M (-8% YoY), raises FY25 revenue guidance to $72-76M

  Net loss $11.9M ($0.23 loss per share) vs $12.3M loss in prior year.

• Jun 05, 2025 23:59 UTC leadership materiality 0.35 neutral item 5.02item 5.07

  Sight Sciences appoints Gerhard Burbach to Board; annual meeting elects directors and ratifies auditor

  Gerhard F. Burbach appointed to Board and Audit Committee (appointment previously disclosed April 21, 2025).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.72 · Most common event earnings

5 positive 1 negative 6 neutral

source · SGHT on sec.gov